Overview
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples.
Our Research Services team works collaboratively with clients to provide in vitro hepatic modeling solutions. And as the world’s premier supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.
Funding rounds
Disclosed funding: $45M across 4 rounds. Latest: Venture Round, 8 Jun 2026.
3 rounds have an undisclosed amount, not included in the total.
| Date | Type | Amount |
|---|---|---|
| 8 Jun 2026 | Venture Round | Not disclosed |
Similar companies
- Discovery Life SciencesBiotechnology Research · Huntsville, Alabama
- Thermo Fisher ScientificBiotechnology Research · Waltham, MA
- Fidelis, A BioIVT CompanyBiotechnology Research · Sofia, Sofia-grad
- BeCytes BiotechnologiesBiotechnology Research · Barcelona, Cataluña / Catalunya
- Charles River LaboratoriesBiotechnology Research · Wilmington, Massachusetts
- Asterand BioscienceBiotechnology Research · Detroit, Michigan
- RocheBiotechnology Research
- Vertex PharmaceuticalsBiotechnology Research · Boston, MA
- LonzaPharmaceutical Manufacturing
- IQVIAHospitals and Health Care · Durham, North Carolina
Latest videos from BioIVT on YouTube
ADME 101: Reaction Phenotyping Studies
From Biology to Decisions: Designing NAM Workflows to Build Scientific and Translational Confidence
Evolving Oncology Biomarker Discovery–Why Multi-Omic Strategies Are Reshaping Translational Research
Evaluating DDI Risk in Emerging Drug Modalities